Secondary KIT mutations: the GIST of drug resistance and sensitivity

Pharmacological targeting of KIT in gastrointestinal stromal tumours has dramatically changed the clinical outcome of this disease. Tyrosine kinase inhibitors are the cornerstone of this improvement, but resistance occurs through secondary KIT mutations. Studies aimed at improving our understanding...

Descripción completa

Detalles Bibliográficos
Autores principales: Napolitano, Andrea, Vincenzi, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461933/
https://www.ncbi.nlm.nih.gov/pubmed/30792534
http://dx.doi.org/10.1038/s41416-019-0388-7
_version_ 1783410555853209600
author Napolitano, Andrea
Vincenzi, Bruno
author_facet Napolitano, Andrea
Vincenzi, Bruno
author_sort Napolitano, Andrea
collection PubMed
description Pharmacological targeting of KIT in gastrointestinal stromal tumours has dramatically changed the clinical outcome of this disease. Tyrosine kinase inhibitors are the cornerstone of this improvement, but resistance occurs through secondary KIT mutations. Studies aimed at improving our understanding of the molecular basis of sensitivity and resistance will soon allow us to further tailor our therapeutic strategies.
format Online
Article
Text
id pubmed-6461933
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-64619332020-02-22 Secondary KIT mutations: the GIST of drug resistance and sensitivity Napolitano, Andrea Vincenzi, Bruno Br J Cancer Editorial Pharmacological targeting of KIT in gastrointestinal stromal tumours has dramatically changed the clinical outcome of this disease. Tyrosine kinase inhibitors are the cornerstone of this improvement, but resistance occurs through secondary KIT mutations. Studies aimed at improving our understanding of the molecular basis of sensitivity and resistance will soon allow us to further tailor our therapeutic strategies. Nature Publishing Group UK 2019-02-22 2019-03-19 /pmc/articles/PMC6461933/ /pubmed/30792534 http://dx.doi.org/10.1038/s41416-019-0388-7 Text en © Cancer Research UK 2019 https://creativecommons.org/licenses/by/4.0/This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution 4.0 International (CC BY 4.0).
spellingShingle Editorial
Napolitano, Andrea
Vincenzi, Bruno
Secondary KIT mutations: the GIST of drug resistance and sensitivity
title Secondary KIT mutations: the GIST of drug resistance and sensitivity
title_full Secondary KIT mutations: the GIST of drug resistance and sensitivity
title_fullStr Secondary KIT mutations: the GIST of drug resistance and sensitivity
title_full_unstemmed Secondary KIT mutations: the GIST of drug resistance and sensitivity
title_short Secondary KIT mutations: the GIST of drug resistance and sensitivity
title_sort secondary kit mutations: the gist of drug resistance and sensitivity
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6461933/
https://www.ncbi.nlm.nih.gov/pubmed/30792534
http://dx.doi.org/10.1038/s41416-019-0388-7
work_keys_str_mv AT napolitanoandrea secondarykitmutationsthegistofdrugresistanceandsensitivity
AT vincenzibruno secondarykitmutationsthegistofdrugresistanceandsensitivity

Ejemplares similares